Bioprocess companies like Sartorius are seeing the demand for CGT equipment and services become an increasingly large proportion of their biologics revenue. René Fáber, who recently tookover as CEO of bioprocess unit Sartorius Stedim Biotech (SSB), said cell culture media and critical materials used to make “new therapeutic modalities like cell and gene therapies (CGTs)” are becoming a “highly relevant portfolio for us” His comment came off the back of the closure of Sartorius’s $2.6 billion acquisition of Polyplus this week.…
